A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review)

Author：

ISSN： 1792-1074

Source： Oncology Letters, Vol.8, Iss.4, 2014-01, pp. : 1391-1396

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Ribonucleotide Reductase Inhibition in the Treatment of Advanced Prostate Cancer: an Experimental Approach with Hydroxyurea and Gallium Nitrate in 20 Patients

By Santarossa S. Vaccher E. Lenardon O. Merlo A. Errante D. Tirelli U.

European Journal of Cancer, Vol. 31, Iss. 10, 1995-09 ,pp. : 1718-1718

Elsevier

Access to resources Recommend Favorite

Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer

By Sharifi Nima

Future Oncology, Vol. 7, Iss. 11, 2011-11 ,pp. : 1239-1241

Future Medicine

Access to resources Recommend Favorite

Supportive care for men with prostate cancer: why are the trials not working? A systematic review and recommendations for future trials

Cancer Medicine, Vol. 4, Iss. 8, 2015-08 ,pp. : 1240-1251

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prostate cancer prevention trials in the USA

By Brawley O.W. Parnes H.

European Journal of Cancer, Vol. 36, Iss. 10, 2000-06 ,pp. : 1312-1315

Elsevier

Access to resources Recommend Favorite

Angiogenesis Inhibition in the Treatment of Prostate Cancer

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 10, 2009-12 ,pp. : 1070-1078

Bentham Science Publishers

Access to resources Recommend Favorite